FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed